Document Detail


Impact of electro-acupuncture and physical exercise on hyperandrogenism and oligo/amenorrhea in women with polycystic ovary syndrome: a randomized controlled trial.
MedLine Citation:
PMID:  20943753     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Polycystic ovary syndrome (PCOS), the most common endocrine disorder in women of reproductive age, is characterized by hyperandrogenism, oligo/amenorrhea, and polycystic ovaries. We aimed to determine whether low-frequency electro-acupuncture (EA) would decrease hyperandrogenism and improve oligo/amenorrhea more effectively than physical exercise or no intervention. We randomized 84 women with PCOS, aged 18-37 yr, to 16 wk of low-frequency EA, physical exercise, or no intervention. The primary outcome measure changes in the concentration of total testosterone (T) at week 16 determined by gas and liquid chromatography-mass spectrometry was analyzed by intention to treat. Secondary outcome measures were changes in menstrual frequency; concentrations of androgens, estrogens, androgen precursors, and glucuronidated androgen metabolites; and acne and hirsutism. Outcomes were assessed at baseline, after 16 wk of intervention, and after a 16-wk follow-up. After 16 wk of intervention, circulating T decreased by -25%, androsterone glucuronide by -30%, and androstane-3α,17β-diol-3-glucuronide by -28% in the EA group (P = 0.038, 0.030, and 0.047, respectively vs. exercise); menstrual frequency increased to 0.69/month from 0.28 at baseline in the EA group (P = 0.018 vs. exercise). After the 16-wk follow-up, the acne score decreased by -32% in the EA group (P = 0.006 vs. exercise). Both EA and exercise improved menstrual frequency and decreased the levels of several sex steroids at week 16 and at the 16-wk follow-up compared with no intervention. Low-frequency EA and physical exercise improved hyperandrogenism and menstrual frequency more effectively than no intervention in women with PCOS. Low-frequency EA was superior to physical exercise and may be useful for treating hyperandrogenism and oligo/amenorrhea.
Authors:
Elizabeth Jedel; Fernand Labrie; Anders Odén; Göran Holm; Lars Nilsson; Per Olof Janson; Anna-Karin Lind; Claes Ohlsson; Elisabet Stener-Victorin
Related Documents :
6517573 - Effects of exercise on the physical fitness, intelligence, and adaptive behavior of ins...
2712803 - Modulation of human plasma fibronectin levels following exercise.
4006073 - Detection of a deuterium isotope effect in di- and trisubstituted alkylphenylnitrosoure...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2010-10-13
Journal Detail:
Title:  American journal of physiology. Endocrinology and metabolism     Volume:  300     ISSN:  1522-1555     ISO Abbreviation:  Am. J. Physiol. Endocrinol. Metab.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-29     Completed Date:  2011-01-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100901226     Medline TA:  Am J Physiol Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  E37-45     Citation Subset:  IM    
Affiliation:
Osher Center for Integrative Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00484705
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acneiform Eruptions / therapy
Adolescent
Adult
Amenorrhea / therapy*
Androstane-3,17-diol / analogs & derivatives,  blood,  chemistry
Androsterone / analogs & derivatives,  blood,  chemistry
Combined Modality Therapy / adverse effects
Electroacupuncture* / adverse effects
Exercise*
Female
Humans
Hyperandrogenism / blood,  therapy*
Menstrual Cycle
Motor Activity*
Oligomenorrhea / therapy*
Polycystic Ovary Syndrome / blood,  physiopathology,  therapy*
Severity of Illness Index
Testosterone / blood,  chemistry
Time Factors
Young Adult
Chemical
Reg. No./Substance:
1852-43-3/androsterone glucuronide; 25126-76-5/Androstane-3,17-diol; 27195-25-1/androstane-3,17-diol glucuronide; 53-41-8/Androsterone; 58-22-0/Testosterone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Coffee polyphenols suppress diet-induced body fat accumulation by downregulating SREBP-1c and relate...
Next Document:  Somatostatin and its receptors contribute in a tissue-specific manner to the sex-dependent metabolic...